- $2.11bn
- $1.69bn
- $1.12bn
Novavax rises after lifting annual revenue forecast
Novavax raises annual revenue forecast on strength of vaccine deals (updated)
Novavax beats quarterly revenue estimates on milestone payment
What to Watch in the Day Ahead - Thursday, November 6
Brief: Novavax Transfers U.S. Marketing Rights for Nuvaxovid to Sanofi, Triggering $25 Million Milestone Payment
Brief: Novavax - FDA Approves Transfer Of Nuvaxovid Authorization To Sanofi - SEC Filing
Live Markets: Nuclear stocks are some of the most shorted names in the US
Novavax signs $60 million agreements to trim US portfolio (updated)
Novavax to lease out one of its US facilities for $60 million
U.S. STOCKS ON THE MOVE-Spyre Therapeutics, Astria, Walmart
U.S. STOCKS ON THE MOVE-Spyre Therapeutics, Astria, Walmart
Novavax top investor urges sale over poor COVID shot rollout; shares rise
U.S. STOCKS ON THE MOVE-Johnson & Johnson, General Motors, BlackRock
Shah Capital pushes for Novavax's sale on persistent underperformance, marketing missteps (updated)
U.S. STOCKS ON THE MOVE-Goldman Sachs, Domino's Pizza, Pattern Group
Novavax falls as top investor urges sale over poor COVID shot rollout
Brief: Shah Capital Recommends Immediate Formal Strategic Review For Sale Of Novavax
Shah Capital pushes for Novavax's sale on persistent underperformance, marketing missteps
New US COVID guidelines add confusion, complications for Americans seeking shots